Sean Fain

Open enrollment with an early-phase pipeline tilt

According to ClinicalTrials.gov-derived indexes, Sean Fain sits in the upper half of US sponsors by registered trial count (#4,885 of 15,742 sponsors by registered trial count).

2 total trials 2 currently recruiting early-phase tilt upper half by trial count

Sean Fain: 2 sponsored US clinical trials, 2 recruiting.

Sean Fain sponsors 2 registered US clinical trials on ClinicalTrials.gov, 2 of them currently recruiting. 0 of these trials are in Phase 3-4 (later-stage) and 2 in Phase 1-2 (earlier-stage). The most-studied condition in this pipeline is Chronic Lung Allograft Dysfunction Lung MRI (CLAD), with 1 trials.

Mid-pack sponsor footprint

Sean Fain is in the upper half of sponsors by trial count (#4,885 of 15,742 sponsors by registered trial count). Use the pipeline list and therapeutic areas to see what drives that mid-pack volume.

What is open in the Sean Fain pipeline

2 recruiting of 2 indexed (100% open).

Phase mix: 0 late (III/IV) vs 2 early (I/II) (early-phase heavy).

Top condition: Chronic Lung Allograft Dysfunction Lung MRI (CLAD) (1 trial), 1 other listed.

How open-pipeline share is computed

Recruiting share is recruiting_count divided by trial_count for this sponsor in the public registry export. Status can change between pulls; treat the figure as a research-attention snapshot, not product availability.

Sean Fain: open-pipeline peers nationwide

Peers matched on 2 registered trials and 100% open enrollment, not the therapeutic-area sidebar.

Sean Fain sits at or above the median trial volume and at or above the median recruiting share among these 9 nationwide peers -- the two do not always move together. Source: ClinicalTrials.gov (2026-08-08 snapshot). 2×2 strategic matrix plotting 9 entities by Total trials (X) and Recruiting share (Y), with a crosshair dividing the plot into four quadrants. Higher volume & more openFocused & more openHigher volume, mostly closedSmaller & mostly closed 1.522.533.544.5 0%50%100%150% Total trials Recruiting share Sean Fain1200 Pharma1ST Biotherapeutics3 Waves Wellness3EO HealthAAVantgarde Bio SrlAcorn BiolabsAcrivon TherapeuticsADARx Pharmaceuticals
Sean Fain sits at or above the median trial volume and at or above the median recruiting share among these 9 nationwide peers -- the two do not always move together. Source: ClinicalTrials.gov (2026-08-08 snapshot).

Sean Fain sits at or above the median trial volume and at or above the median recruiting share among these 9 nationwide peers -- the two do not always move together.

Sponsors near 2 trials (± recruiting share)

Sponsors near 100% open enrollment (± trial volume)

What to do with this Sean Fain page

2 registered trials is a research-attention snapshot, not an endorsement of Sean Fain or any single study.

Trial and recruiting counts reflect ClinicalTrials.gov registry status as of the data vintage above; individual trial eligibility and enrollment status can change.

Sean Fain pipeline card: 2 registered trials from official public datasets.Report a data error.